
The $2.4B Oral Macrocycle and Bispecific Surge: Why Big Pharma Is Buying Platform Engines Over Single Assets
Dr. Dereck Mush, MD, MBANo. 31 Investors
Partner, Alkeon Capital Management • United States
He invests in artificial intelligence and healthcare software companies.
Find on LinkedInHis dual background as a physician and investor offers deep insight into clinical AI. He regularly teaches and publishes on validating AI models for safe clinical use.
He invests in artificial intelligence and healthcare software companies.
His dual background as a physician and investor offers deep insight into clinical AI. He regularly teaches and publishes on validating AI models for safe clinical use.
Loading the full dossier
Audience size across LinkedIn, X, YouTube, podcasts and newsletters.
How much the audience actually reacts, comments, shares and subscribes.
Clinical, research, operating or investing track record behind the commentary.
Publishing cadence and how reliably they show up with original work.
Whether decision makers, policy and capital actually move on what they say.
Scores are subjective editorial estimates compiled by our research desk from public profiles and published work. They are opinion, not measurement, and they are not a judgement of any person's character or ability.
Change, add or remove details on this profile. Our desk reviews every request.
This profile is compiled by our research desk from public sources and is published as editorial commentary. Want a correction, an update, or your profile removed? and see our corrections and removals policy.

Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBAKeep exploring